Lexaria Bioscience Says Follow-Up Study Confirmed DehydraTECHTM-CBD Lowers Arterial Stiffness; Shares Rise

10:28AM ET 12/08/2021 MT Newswires
Lexaria Bioscience (LEXX) said Wednesday follow-up results from a human clinical study confirmed that a single day of dosing with the company's DehydraTECHTM-processed cannabidiol lowers arterial stiffness.

The company said it will now investigate the formulation in a six-week hypertension study with multiple doses to explore its application to treat cardiovascular and other disease states beyond hypertension.

Lexaria shares were up 4.9% in recent trading.

Price: 1.72, Change: +0.09, Percent Change: +5.52